Therefore, we determined the ability of those two anticancer candidates, miR-34a and PLK1-siRNA complexed with our APA nanocarrier, to inhibit the tumorigenicity of pancreatic cancer cells. This evidence concerns the gene PLK1 and familial pancreatic carcinoma.